


IFW

ALS-2



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Stec et al) : Examiner: D. Clayton
Application No.: 10/622,302) : Group Art Unit: 1617
Filed: July 18, 2003) :
For: Use of 2,3-alkylcarbonyloxybenzoic)
Acids, Derivatives and Analogues : November 3, 2006
Therefrom in the Treatment of Tissue and
Cellular Dysfunction, Damage and Injury in
Mammals

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE

Sir:

This paper is presented in response to the office action dated October 11, 2006 in the above-referenced application.

The application is objected to as failing to provide a proper election of species. Specifically, the Examiner has stated that Applicant has failed to properly elect a species of a therapeutic agent or compound.

To reiterate Applicant's election from Applicant's previous response, Applicant has identified "agents for prevention and treatment of myocardial infarction" as the therapeutic agent administered together with the 2,3-alkylcarbonyloxybenzoic acid. To respond to the Examiner's continued objection, Applicant now identifies alteplase as the species of the myocardial infarction prevention/treatment agent.

No fees appear to be due in connection with this filing. Applicant's attorney can be reached at the phone numbers listed below.

Respectfully submitted,



Jeffrey M. Hoster
Attorney for Applicant
Registration No. 32,240

Jeffrey M. Hoster, Ltd
13 Woodland Drive
Lemont, IL 60439
Phone Nos.: (630) 243-6610 or (630) 247-6449

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 3 March 2016.